Cargando…
Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study
In this retrospective cohort study, we evaluated the efficacy of baricitinib in the treatment of coronavirus disease 2019 (COVID-19). Among 404 adult patients with COVID-19 who were admitted to our hospital between October 23, 2020, and July 31, 2021, 229 patients with respiratory failure were inclu...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Respiratory Society. Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898743/ https://www.ncbi.nlm.nih.gov/pubmed/35307364 http://dx.doi.org/10.1016/j.resinv.2022.02.004 |
_version_ | 1784663726456045568 |
---|---|
author | Tanimoto, Takuya Tada, Shinpei Fujita, Suguru Hirakawa, Tetsu Matsumura, Mirai Isoyama, Shoko Ueno, Sayaka Hamai, Kosuke Tsuji, Naoki Hirosawa, Hideyasu Taniguchi, Tomohiro Okamoto, Takeshi Omoto, Takuji Kusunoki, Shinji Maeda, Hiroyuki Ishikawa, Nobuhisa |
author_facet | Tanimoto, Takuya Tada, Shinpei Fujita, Suguru Hirakawa, Tetsu Matsumura, Mirai Isoyama, Shoko Ueno, Sayaka Hamai, Kosuke Tsuji, Naoki Hirosawa, Hideyasu Taniguchi, Tomohiro Okamoto, Takeshi Omoto, Takuji Kusunoki, Shinji Maeda, Hiroyuki Ishikawa, Nobuhisa |
author_sort | Tanimoto, Takuya |
collection | PubMed |
description | In this retrospective cohort study, we evaluated the efficacy of baricitinib in the treatment of coronavirus disease 2019 (COVID-19). Among 404 adult patients with COVID-19 who were admitted to our hospital between October 23, 2020, and July 31, 2021, 229 patients with respiratory failure were included. Among these, 41 patients in the baricitinib group and 41 patients in the control group were selected by propensity score matching to adjust for background factors. We compared the survival rates of the two groups at 30 and 60 days after admission. The 30-day survival rate was significantly higher in the baricitinib group than in the control group. However, there was no significant difference in 60-day survival in the two groups. Baricitinib may improve the early prognosis of patients with respiratory failure associated with COVID-19. However, efforts should be made to improve the long-term prognosis. |
format | Online Article Text |
id | pubmed-8898743 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Japanese Respiratory Society. Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88987432022-03-07 Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study Tanimoto, Takuya Tada, Shinpei Fujita, Suguru Hirakawa, Tetsu Matsumura, Mirai Isoyama, Shoko Ueno, Sayaka Hamai, Kosuke Tsuji, Naoki Hirosawa, Hideyasu Taniguchi, Tomohiro Okamoto, Takeshi Omoto, Takuji Kusunoki, Shinji Maeda, Hiroyuki Ishikawa, Nobuhisa Respir Investig Rapid Communication In this retrospective cohort study, we evaluated the efficacy of baricitinib in the treatment of coronavirus disease 2019 (COVID-19). Among 404 adult patients with COVID-19 who were admitted to our hospital between October 23, 2020, and July 31, 2021, 229 patients with respiratory failure were included. Among these, 41 patients in the baricitinib group and 41 patients in the control group were selected by propensity score matching to adjust for background factors. We compared the survival rates of the two groups at 30 and 60 days after admission. The 30-day survival rate was significantly higher in the baricitinib group than in the control group. However, there was no significant difference in 60-day survival in the two groups. Baricitinib may improve the early prognosis of patients with respiratory failure associated with COVID-19. However, efforts should be made to improve the long-term prognosis. The Japanese Respiratory Society. Published by Elsevier B.V. 2022-05 2022-03-07 /pmc/articles/PMC8898743/ /pubmed/35307364 http://dx.doi.org/10.1016/j.resinv.2022.02.004 Text en © 2022 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Rapid Communication Tanimoto, Takuya Tada, Shinpei Fujita, Suguru Hirakawa, Tetsu Matsumura, Mirai Isoyama, Shoko Ueno, Sayaka Hamai, Kosuke Tsuji, Naoki Hirosawa, Hideyasu Taniguchi, Tomohiro Okamoto, Takeshi Omoto, Takuji Kusunoki, Shinji Maeda, Hiroyuki Ishikawa, Nobuhisa Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study |
title | Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study |
title_full | Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study |
title_fullStr | Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study |
title_full_unstemmed | Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study |
title_short | Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study |
title_sort | effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: a propensity score-matched retrospective cohort study |
topic | Rapid Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898743/ https://www.ncbi.nlm.nih.gov/pubmed/35307364 http://dx.doi.org/10.1016/j.resinv.2022.02.004 |
work_keys_str_mv | AT tanimototakuya effectofbaricitinibinpatientswithcoronavirusdisease2019andrespiratoryfailureapropensityscorematchedretrospectivecohortstudy AT tadashinpei effectofbaricitinibinpatientswithcoronavirusdisease2019andrespiratoryfailureapropensityscorematchedretrospectivecohortstudy AT fujitasuguru effectofbaricitinibinpatientswithcoronavirusdisease2019andrespiratoryfailureapropensityscorematchedretrospectivecohortstudy AT hirakawatetsu effectofbaricitinibinpatientswithcoronavirusdisease2019andrespiratoryfailureapropensityscorematchedretrospectivecohortstudy AT matsumuramirai effectofbaricitinibinpatientswithcoronavirusdisease2019andrespiratoryfailureapropensityscorematchedretrospectivecohortstudy AT isoyamashoko effectofbaricitinibinpatientswithcoronavirusdisease2019andrespiratoryfailureapropensityscorematchedretrospectivecohortstudy AT uenosayaka effectofbaricitinibinpatientswithcoronavirusdisease2019andrespiratoryfailureapropensityscorematchedretrospectivecohortstudy AT hamaikosuke effectofbaricitinibinpatientswithcoronavirusdisease2019andrespiratoryfailureapropensityscorematchedretrospectivecohortstudy AT tsujinaoki effectofbaricitinibinpatientswithcoronavirusdisease2019andrespiratoryfailureapropensityscorematchedretrospectivecohortstudy AT hirosawahideyasu effectofbaricitinibinpatientswithcoronavirusdisease2019andrespiratoryfailureapropensityscorematchedretrospectivecohortstudy AT taniguchitomohiro effectofbaricitinibinpatientswithcoronavirusdisease2019andrespiratoryfailureapropensityscorematchedretrospectivecohortstudy AT okamototakeshi effectofbaricitinibinpatientswithcoronavirusdisease2019andrespiratoryfailureapropensityscorematchedretrospectivecohortstudy AT omototakuji effectofbaricitinibinpatientswithcoronavirusdisease2019andrespiratoryfailureapropensityscorematchedretrospectivecohortstudy AT kusunokishinji effectofbaricitinibinpatientswithcoronavirusdisease2019andrespiratoryfailureapropensityscorematchedretrospectivecohortstudy AT maedahiroyuki effectofbaricitinibinpatientswithcoronavirusdisease2019andrespiratoryfailureapropensityscorematchedretrospectivecohortstudy AT ishikawanobuhisa effectofbaricitinibinpatientswithcoronavirusdisease2019andrespiratoryfailureapropensityscorematchedretrospectivecohortstudy |